Cidara Therapeutics to Present at the Stifel Healthcare Conference
11/08/2022 - 08:00 AM
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference.
Cidara’s presentation will be available on-demand from the above date/time in the Investors section on the Company’s website at www.cidara.com . The replay of the presentation will be available for 90 days.
About Cidara Therapeutics ® platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com .
INVESTOR CONTACT:
MEDIA CONTACT:
CDTX Rankings
#734 Ranked by Stock Gains
CDTX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
San Diego
About CDTX
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
